# A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2

> **NCT05113862** · PHASE1 · COMPLETED · sponsor: **Gylden Pharma Ltd** · enrollment: 26 (actual)

## Conditions studied

- Coronavirus
- SARS-CoV-2 Infection
- COVID-19

## Interventions

- **BIOLOGICAL:** LD Vehicle-GNP
- **BIOLOGICAL:** LD PepGNP-Covid19
- **BIOLOGICAL:** HD Vehicle-GNP
- **BIOLOGICAL:** HD PepGNP-Covid19

## Key facts

- **NCT ID:** NCT05113862
- **Lead sponsor:** Gylden Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-10
- **Primary completion:** 2022-09-15
- **Final completion:** 2022-09-15
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-02-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05113862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05113862, "A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05113862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*